Literature DB >> 1546650

Reproducibility of head-up tilt-table testing for eliciting susceptibility to neurally mediated syncope in patients without structural heart disease.

X C Chen1, M Y Chen, S Remole, Y Kobayashi, A Dunnigan, S Milstein, D G Benditt.   

Abstract

Head-up tilt testing has gained acceptance as a tool for assessing susceptibility to neurally mediated syncopal syndromes (e.g., vasovagal syncope), and is currently being evaluated as a means of testing therapeutic interventions in these conditions. To assess reproducibility of head-up tilt testing and thereby assess the potential of such testing for immediate evaluation of a planned treatment, findings during 2 sequential 80 degrees head-up tilt tests were compared in 23 patients (age range 6.5 to 74 years) undergoing evaluation of syncope of unknown origin. Upright tilt was performed initially in the absence of drugs, and repeated if necessary during pharmacologic provocation by means of isoproterenol infusions of 1 and 3 micrograms/min (tilt 1). End points were syncope, maximal tolerated isoproterenol dose, or a tilt duration of 10 minutes. The second tilt test (tilt 2) was conducted after approximately 30 minutes of supine rest using the maximal provocative conditions used in tilt 1. Fifteen of 23 patients (65%) developed syncope in either tilt 1 or 2, while 8 of 23 (35%) remained asymptomatic. Tilt testing results were concordant (i.e., positive in both tests, or negative in both tests) in 20 of 23 (87%) patients. Concordance was, however, less among tilt-positive patients (12 of 15, 80%) since 3 patients were tilt-positive in tilt 1 only.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546650     DOI: 10.1016/0002-9149(92)90501-o

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Determining the optimal pacing intervention rate for vasovagal syncope.

Authors:  A S Kurbaan; A C Franzén; Z Stack; D Heaven; G Mathur; R Sutton
Journal:  J Interv Card Electrophysiol       Date:  2000-12       Impact factor: 1.900

Review 2.  The fainting patient: value of the head-upright tilt-table test in adult patients with orthostatic intolerance.

Authors:  M Lamarre-Cliche; J Cusson
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

3.  Pathogenesis and management of delayed orthostatic hypotension in patients with chronic fatigue syndrome.

Authors:  F De Lorenzo; J Hargreaves; V V Kakkar
Journal:  Clin Auton Res       Date:  1997-08       Impact factor: 4.435

4.  Comparison of the active standing test and head-up tilt test for diagnosis of syncope in childhood and adolescence.

Authors:  Reiko Matsushima; Hidetaka Tanaka; Hiroshi Tamai
Journal:  Clin Auton Res       Date:  2004-12       Impact factor: 4.435

5.  Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.

Authors:  M Biffi; G Boriani; P Sabbatani; G Bronzetti; L Frabetti; R Zannoli; A Branzi; B Magnani
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

6.  Orthostatic tolerance in patients with unexplained syncope.

Authors:  R Hainsworth; K M el-Bedawi
Journal:  Clin Auton Res       Date:  1994-10       Impact factor: 4.435

Review 7.  Hemodynamic orthostatic dizziness/vertigo: Diagnostic criteria.

Authors:  Hyun Ah Kim; Alexandre Bisdorff; Adolfo M Bronstein; Thomas Lempert; Marcos Rossi-Izquierdo; Jeffrey P Staab; Michael Strupp; Ji-Soo Kim
Journal:  J Vestib Res       Date:  2019       Impact factor: 2.354

Review 8.  Neurohormones in the Pathophysiology of Vasovagal Syncope in Adults.

Authors:  David G Benditt; J Gert van Dijk; Darshan Krishnappa; Wayne O Adkisson; Scott Sakaguchi
Journal:  Front Cardiovasc Med       Date:  2020-05-06

9.  Tilt testing remains a valuable asset.

Authors:  Richard Sutton; Artur Fedorowski; Brian Olshansky; J Gert van Dijk; Haruhiko Abe; Michele Brignole; Frederik de Lange; Rose Anne Kenny; Phang Boon Lim; Angel Moya; Stuart D Rosen; Vincenzo Russo; Julian M Stewart; Roland D Thijs; David G Benditt
Journal:  Eur Heart J       Date:  2021-05-01       Impact factor: 35.855

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.